Data / Drug companies / Takeda Pharmaceuticals America, Inc.
Takeda Pharmaceuticals America, Inc.: 48 products in the FDA NDC directory, labeler code 0944
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Takeda Pharmaceuticals America, Inc. (labeler code 0944) lists 48 products in the FDA National Drug Code Directory, covering 14 finished drugs by generic name. By type: 48 plasma derivatives. Its main marketing category is biologics (BLA). The newest product started marketing on July 14, 2025.
The request: Watch Takeda Pharmaceuticals America, Inc. (FDA labeler code 0944): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0944
- Products in commercial distribution
- 48
- Packages
- 61
- Finished drugs by generic name
- 14
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- February 23, 1988
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Biologics (BLA) | 48 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Plasma derivatives | 48 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Antihemophilic factor (recombinant) | 7 | 4 |
| Antihemophilic factor (recombinant) pegylated | 7 | 1 |
| Coagulation factor ix (recombinant) | 5 | 3 |
| Antihemophilic factor recombinant | 5 | 2 |
| Antihemophilic factor human | 4 | 1 |
| Immune globulin intravenous (human) | 2 | 3 |
| Alpha-1-proteinase inhibitor (human) | 2 | 2 |
| Protein c concentrate human | 2 | 1 |
| Albumin human | 2 | 3 |
| Immune globulin infusion (human) | 2 | 1 |
| Von willebrand factor (recombinant) | 2 | 1 |
| Immune globulin subcutaneous (human) | 1 | 1 |
| Antihemophilic factor (recombinant), porcine sequence | 1 | 1 |
| Alpha.1-proteinase inhibitor human | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Kit | 42 | 87.5% |
| Injection, solution | 5 | 10.4% |
| Solution | 1 | 2.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Human Immunoglobulin G | 3 |
| Human Serum Albumin | 2 |
| Human alpha-1 Proteinase Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| GAMMAGARD Liquid ERC | 0944-2705 | Injection, solution | Biologics (BLA) | July 14, 2025 |
| Adynovate | 0944-4628 | Kit | Biologics (BLA) | October 25, 2016 |
| Adynovate | 0944-4626 | Kit | Biologics (BLA) | October 25, 2016 |
| Adynovate | 0944-4624 | Kit | Biologics (BLA) | October 25, 2016 |
| Cuvitru | 0944-2850 | Injection, solution | Biologics (BLA) | October 18, 2016 |
| Adynovate | 0944-4622 | Kit | Biologics (BLA) | July 28, 2016 |
| Vonvendi | 0944-7553 | Kit | Biologics (BLA) | December 8, 2015 |
| Vonvendi | 0944-7551 | Kit | Biologics (BLA) | December 8, 2015 |
| Adynovate | 0944-4627 | Kit | Biologics (BLA) | November 13, 2015 |
| Adynovate | 0944-4625 | Kit | Biologics (BLA) | November 13, 2015 |
| Adynovate | 0944-4623 | Kit | Biologics (BLA) | November 13, 2015 |
| Obizur | 0944-5001 | Kit | Biologics (BLA) | October 23, 2014 |
| Hyqvia | 0944-2514 | Kit | Biologics (BLA) | September 12, 2014 |
| Hyqvia | 0944-2513 | Kit | Biologics (BLA) | September 12, 2014 |
| Hyqvia | 0944-2512 | Kit | Biologics (BLA) | September 12, 2014 |
| Hyqvia | 0944-2511 | Kit | Biologics (BLA) | September 12, 2014 |
| Hyqvia | 0944-2510 | Kit | Biologics (BLA) | September 12, 2014 |
| Flexbumin | 0944-0495 | Injection, solution | Biologics (BLA) | July 31, 2014 |
| Rixubis | 0944-3034 | Kit | Biologics (BLA) | October 4, 2013 |
| Rixubis | 0944-3032 | Kit | Biologics (BLA) | October 4, 2013 |
| Rixubis | 0944-3030 | Kit | Biologics (BLA) | October 4, 2013 |
| Rixubis | 0944-3028 | Kit | Biologics (BLA) | October 4, 2013 |
| Rixubis | 0944-3026 | Kit | Biologics (BLA) | October 4, 2013 |
| Advate | 0944-3047 | Kit | Biologics (BLA) | July 12, 2012 |
| Advate | 0944-3054 | Kit | Biologics (BLA) | December 15, 2011 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.